Kornimate/medical-research-clean huggingface dataset:
evaluation of ambulatory ecg telemetry for the early detection of atrial fibrillation during hospital assessment of cerebral infarction

Conditions: Cerebral Infarction

Summary: the aim of the study is to show that an ambulatory ecg telemetry monitoring of some patients hospitalized for cerebral infarction increases the frequency of the diagnosis of atrial fibrillation, cause of their stroke, and reinforces the protection against recurrences.


Eligibility criteria:
inclusion criteria: * patients over 18 years old * diagnosis of transient ischemic or cerebral accident * absence of etiological orientation after the initial assessment (including at least cerebral mri, angiography of the supra aortic trunks by ct or mri, echocardiography with search for patent foramen ovale, standard biology) * affiliated to a social security system. * having given no opposition to participation in research exclusion criteria: * af known or diagnosed during stay in usinv

Keywords: stroke ecg telemetry atrial fibrillation
the pharmacological basis for the increase in visual time constants induced by single oral doses of sildenafil

Conditions: Erectile Dysfunction

Summary: sildenafil and similar drugs have been used for several years to treat erectile dysfunction. it has been noticed that in some people, sildenafil causes a subtle increase in the length of time that visual images that we see are retained by the retina. it is thought that this might be due to an effect of sildenafil on inhibiting an enzyme called phosphodiesterase type 6 (pde6) which is present in the retina. by giving single oral doses of sildenafil and a similar drug called tadalafil which has less effect on pde6, we hypothesise that this is the mechanism of the change in vision caused by sildenafil. by performing computerised visual test, we plan to compare the effects of sildenafil, tadalafil and placebo tablets on vision in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy * male * 18-55 years exclusion criteria: * significant medical or psychiatric illness * cardiac disease * hyper or hypotension * renal disease * liver disease * stroke * sickle cell anaemia * multiple myeloma * leukaemia * bleeding disorders * peyronie's disease * priapism * subjects receiving prescribed medications * subjects with known visual abnormalities other than refractive errors, including retinitis pigmentosa, optic neuropathy

Keywords: sildenafil tadalafil phosphodiesterase visual persistence reaction time
comparing therapeutic hypothermia using external and internal cooling for post-cardiac arrest patients

Conditions: Cardiac Arrest

Summary: controlled therapeutic hypothermia is a method of preserving neurological function post-resuscitation.it has been associated with improved functional recovery and reduced histological deficits in animal models of cardiac arrest.

three randomized clinical studies have been reported showing improved neurological outcome and reduced mortality in post-resuscitation patients treated with hypothermia compared to controls. of the various methods of inducing hypothermia, internal cooling using an endovascular catheter and external cooling using gel pads with a water based circulating system have shown the most promise. there have not been any studies looking at outcomes between the two methods of cooling.

Eligibility criteria:
inclusion criteria: 1. sustained return of spontaneous circulation (rosc) after cardiac arrest, for more than 30 min 2. patients aged between 18 to 80 years. 3. patients who are hemodynamically stable, with a systolic bp \> 90 mmhg with or without inotropic support. 4. patients comatose or unresponsive post-resuscitation exclusion criteria: 1. hypotension despite fluid and/or vasopressor support 2. positive pregnancy test in women below 50 years 3. premorbid status bedbound and uncommunicative

Keywords: hypothermia internal cooling external cooling cardiac arrest
a study of hmpl-306 in patients with idh1 and/or idh2 mutation of relapsed/refractory myeloid leukemia/neoplasms

Conditions: Acute Myeloid Leukemia

Summary: phase i, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of hmpl-306 in patients of relapsed/refractory myeloid leukemia/neoplasms with idh1 and/or idh2 mutation.

the purpose of this phase i, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of hmpl-306 in patients of relapsed/refractory myeloid leukemia/neoplasms with idh1 and/or idh2 mutation. the first stage of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of hmpl-306 to determine maximum tolerated dose (mtd) and/or the recommended phase ii dose. the second stage of the study is a dose expansion phase where three cohorts of patients will receive hmpl-306 to further evaluate the safety, tolerability, and clinical activity of the recommended phase ii dose.

Eligibility criteria:
inclusion criteria: * ≥18 years of age; * signed informed consent form; * relapsed/refractory acute myeloid leukemia (aml), myelodysplastic syndrome (mds) or chronic myelomonocytic leukemia(cmml) and others myeloid neoplasm; * idh1 and/or idh2 mutated disease status as assessed by local laboratory; * cooperative oncology group (ecog) performance status of 0-2; * subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study. exclusion criteria: * previously treated with any prior idh1 inhibitor, idh2 inhibitor, or idh1/idh2 double-targeted therapy and had disease progression during treatment; * with known involvement or clinical symptoms of central nervous system (cns); * patients who have undergone hsct within 60 days; * without adequate liver or kidney function; * with known infection with active hepatitis b or c; * with known infection with human immunodeficiency virus (hiv); * history of clinically significant or active cardiac disease; * active clinically significant infection; * taking known strong cytochrome p450 (cyp) 2c8 inducers or inhibitors; * pregnancy or breast-feeding.

Keywords: hmpl-306 idh1 mutation idh2 mutation acute myeloid leukemia myelodysplastic symdrome chronic myelomonocytic leukemia myeloid leukemia/neoplasms
maxillary sinus floor elevation with gelatin sponge versus allogenic demineralized bone matrix

Conditions: Maxillary Sinus Disease

Summary: the post-extraction pneumatization of the maxillary sinus often compromises the ability of the maxillary molar to the optimal recipient of dental implants as a consequence of the quantitative reduction of the vertical bone height and the reduced bone quality of the region posterior maxillary segment.


Eligibility criteria:
inclusion criteria: 1. patients of both sexes, with an age range of (25 to 55 years) with unilateral or bilateral edentulous posterior maxillary molar region with \\ vertical residual bone height of (four to six millimeters), a minimal horizontal bone width of six millimeters bone width, acceptable interarch space, and fair inter-jaw anteroposterior, horizontal and vertical relationships. 2. proper general health and oral hygiene. exclusion criteria: 1. the presence of sinusitis, local sinus pathosis, or a systemic disease that would affect the final treatment outcomes, bone remodeling process, or maxillary sinus health. 2. those patients with a history of previous bone graft, sinus lift, or failed implant.
buprenorphine maintenance for opiate dependence - 6

Conditions: Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to determine the efficacy of buprenorphine as a substitution pharmacotherapy for opiate dependence.


Eligibility criteria:
please contact site for information.

Keywords: opiate dependence
prospective randomised study comparing laparoscopic versus open surgery in patients with rectal cancer

Conditions: RECTAL CANCER

Summary: the aim of this study is to compare laparoscopic versus open approach on the surgical treatment of mid and low-lying rectal cancer, both performed by the same surgical team with experience in open colorectal surgery and advanced laparoscopic surgery, assessing preoperative and anatomopathological results and long-term outcome.


Eligibility criteria:
inclusion criteria: * mid- and low-lying rectal cancer (between 0 and 11 cm from the anal margin) * histology of adenocarcinoma exclusion criteria: * locally advanced disease (t4) * emergency surgery * rectal cancer over familial colic polyposis
treatment pattern of noacs (non-vitamin k oral anticoagulants) in outpatient users in colombian databases

Conditions: Atrial Fibrillation

Summary: this population-based descriptive study will characterize first-time users of three noacs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (spaf) patients and will assess the patterns of drug utilization in routine general practice in colombia


Eligibility criteria:
inclusion criteria: * first prescription of noacs (rivaroxaban, dabigatran and apixaban) in the outpatient setting. * non valvular atrial fibrillation (nvaf) patients * aged ≥18 years * at least one year of enrollment in the audifarma database * one year since first encounter with healthcare provider will be included in the study exclusion criteria: * patients with any record of index drug prescription prior to the enrolment period. * patients who qualify as members of more than one cohort study on the same day
factor ix inhibition in thrombosis prevention (the fixit trial)

Conditions: Venous Thromboembolism; Embolism and Thrombosis; Hip Fractures

Summary: the purpose of this study is to determine whether ttp889 prevents venous thromboembolism following surgery to repair hip fracture.

fixit is the first phase 2 study of ttp889. the trial is a proof-of-concept study to determine the safety and antithrombotic efficacy of ttp889 in patients at risk for venous thromboembolism (vte). the study is a multi-center, randomized, double-blind, parallel-group evaluation of 300 mg ttp889 or placebo, administered orally once daily for three weeks, in patients who have undergone surgery to repair unilateral fracture of the upper third of either femur and who have completed 5 to 9 days of postoperative prophylactic treatment for vte.

Eligibility criteria:
inclusion criteria: * must have undergone reparative surgery within 72 hours after unilateral hip fracture, defined as fracture of the upper third of either femur * must have started standard prophylactic treatment for vte with low molecular weight heparin (lmwh) or heparin before surgery or within 24 hours after hip fracture surgery, and continued treatment with lmwh or heparin for at least five days, but not more than nine days, after surgery * last dose of lmwh or heparin must have been administered at least 12 hours, but not more than 48 hours, before dosing with study drug * females must have a negative serum pregnancy test * must weigh at least 45 kg * must demonstrate the mental and physical ability and willingness to follow all study-specific instructions * must be able to read, comprehend and sign the ethics committee-approved informed consent form exclusion criteria: * evidence of active bleeding * clinical signs of vte * any medical requirement for (or intention to use) continued anticoagulation after randomization through the end of study * history of intracranial bleeding, hemorrhagic stroke, or gastrointestinal bleeding within 3 months of study start * presence of active malignant disease * hip fracture associated with multiple trauma, that places patient at excessive risk for hemorrhage or organ system failure, or that may make it difficult or impossible to perform bilateral lower limb venography * intention to take aspirin at doses greater than 325 mg/day * hemoglobin \< 5.45 mmol/l (9 g/dl), hematocrit \< 29%, or a platelet count \< 100,000/ml at the screening visit * elevated alt or ast level \> 3.0 times the uln, or an elevated total bilirubin \> 1.5 the uln at the screening visit * creatinine \> 180 mmol/l (2.0 mg/dl) at the screening visit * any other laboratory value at screening that the investigator considers to be clinically significant and warrants exclusion from the study * patient is currently breast feeding a child and wishes to continue breast feeding * previous allergy to contrast material or any other contraindications to perform bilateral lower limb venography * the use of another investigational drug within 28 days of study entry

Keywords: antithrombotic agents anticoagulants prophylaxis embolism deep vein thrombosis hip fracture
effect of rilapladib (sb-659032) on platelet aggregation

Conditions: Healthy Subjects; Atherosclerosis

Summary: the purpose of this study is to compare the effects of repeat doses of sb-659032 with placebo on platelet aggregation in subjects.


Eligibility criteria:
inclusion criteria: * subjects with qtc \< 450 msec as measured at screening. exclusion criteria: * history of asthma. * smokers.

Keywords: platelet aggregation sb-659032 rilapladib
botulinum toxin injection efficiency

Conditions: Torticollis; Muscle Spasticity

Summary: the purpose of the study is to examine the effect of the botulinum toxin injection into muscle tone, strength and mobility with and without muscle exercise effect.

the purpose is also to find out patients subjective symptoms between injections. hypothesis: efficiency of the botulinum toxin is more powerful with the muscle exercise before injection.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cervical dystonia * spasticity in splenius capitis muscle * regular treatment with botulinum toxin injection exclusion criteria: * don't want to take part the trial * very long distance from home to jyväskylä central hospital

Keywords: torticollis botulinum toxins
comparison of two biphasic insulin regimens

Conditions: Diabetes Mellitus, Type 2

Summary: comparison of two biphasic insulin regimens in well-controlled patients with the use of continuous glucose monitoring and new glycemic control indices

a cross-over study of 36 well controlled people with type 2 diabetes mellitus who underwent 7-day continuous glucose monitoring with premixed human insulin 30/70 and subsequently with biphasic aspart 30.

Eligibility criteria:
inclusion criteria: * regular attendees of outpatient clinic of the diabetes centre of the 1st department of internal medicine of university hospital in thessaloniki greece * the patients were on premixed human insulin 30/70 twice daily with or without metformin * baseline hba1c\<7% exclusion criteria: * the presence of type 1 diabetes mellitus * stage 4 chronic kidney disease * use of antidiabetic medications other than insulin and metformin * major cardiovascular event during the last six months * acute illness and hospitalization during the last two weeks * pregnancy * absence of good metabolic control assessed with self-monitoring of blood glucose during the week before entering the study (\>20% of the measurements \ 130mg/dl) * inability of the patients to understand the study procedures and sign the consent form

Keywords: diabetes mellitus type 2 glycemic control glycated albumin continuous glucose monitoring fructosamine glycated hemoglobin insulin premixed human insulin premixed insulin analog
effects of the cognitive enhancing ict contents in patients with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to investigate the effect of cognitive rehabilitation program on the improvement of cognitive functions in patients with mild cognitive impairment(mci).

the cognitive rehabilitation program was developed to improve cognitive functions of the elderly or patients with cognitive impairments. the study will enroll 40 patients with mild cognitive impairment(mci) between 55 and 75 years of age. forty subjects will be randomly assigned into two groups. subjects in the intervention group will receive four weeks of cognitive rehabilitation training, three times per week and 30 minutes per day. the control group will not receive any intervention. the investigator will measure their cognitive and brain functions three times at pre-intervention, post-intervention and four weeks after intervention to assess the effectiveness of the cognitive training program.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with mild cognitive impairment through clinical interview, neuropsychological tests and brain imaging * no history of neurologic diseases exclusion criteria: * severe cognitive problems(mmse\<10) * other psychiatric disorder including bipolar or schizophrenic disorder * other problems disturbing cognitive tests

Keywords: mild cognitive impairment cognitive training program
pharmacokinetics study of alo-02 and oxycontin

Conditions: Management of Moderate to Severe Pain

Summary: to characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of alo-02 40 mg twice daily, alo-02 80 mg once daily or oxycontin 40 mg twice daily in healthy volunteers


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. exclusion criteria: * evidence or history of clinically significant diseases.

Keywords: single- and multiple-dose pharmacokinetics alo-02 oxycontin
biorepository of biomarkers for optimization of microvascular treatment of lymphedema

Conditions: Lymphedema

Summary: researchers are collecting information, saliva, blood and tissue from subjects with lymphedema to store for future research.


Eligibility criteria:
inclusion criteria: * adult (18+ years of age) * ability to provide written consent * has been diagnosed with lymphedema exclusion criteria: * under the age of 18 years old * inability to provide written consent * previous lymphovenous bypass or lymph node transfer surgery * major changes occur to co-morbid conditions * proven icg or iodine allergy
endoscopic resection multicenter registry

Conditions: Gastrointestinal Neoplasms; Gastrointestinal Disease; Gastric Cancer; Gastric Neoplasm; Gastric Polyp; Esophageal Neoplasms; Duodenal Neoplasms; Duodenal Polyp; Stomach Neoplasm; Stomach Polyp; Neoplasms; Colon Polyp; Colon Neoplasm

Summary: this is a retrospective and prospective multicenter registry to collect long-term data (1 year) on patients who have or will undergo endoscopic resection such as emr, esd, eftr, ster, etc. within the gastrointestinal tract for endoscopic treatment of early gastrointestinal neoplasms involving the resection of the superficial layers, mucosa and submucosa, of the tract wall. subjects will be consented for medical chart review. the purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of endoscopic resection within the gastrointestinal tract (1 year). the registry will evaluate efficacy, technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review. the procedures the investigators are evaluating are all clinically indicated and will not be prescribed to someone to participate in this registry study.

endoscopic resection can be an appropriate approach in early neoplasms, challenging adenomas or sub-epithelial lesions. endoscopic resection can be considered as a less invasive approach than surgery. moreover, endoscopic resection can be available to patients who are ineligible for surgery or who have refused more aggressive surgical intervention. the study investigators would collect data on a large sample size of subjects undergoing various endoscopic resection procedures such as emr (endoscopic mucosal resection), esd (endoscopic submucosal dissection), ster (submucosal tunneling endoscopic resection, and eftr (endoscopic full-thickness resection). clinical metrics will be recorded including procedure times, length of follow-up, specific tumor characteristics, resection method, pathology results, procedural complications, additional therapy required, and disease-free survival time. currently, there is limited multi-center data on endoscopic resection outcomes in western populations. evaluation of these measurement would help the investigators compare them to conventional treatment modalities within current tertiary facilities; and consequently help the investigators identify appropriate treatment techniques and improve clinical management of patients at wcmc-nyph. the purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of endoscopic resection within the gastrointestinal tract (1 year).

Eligibility criteria:
inclusion criteria: * any patient who is considering undergoing endoscopic resection within 6 months, or has undergone clinically indicated endoscopic resection within the past 6 months * above or equal to 18 years of age. exclusion criteria: * any patient who has not undergone or will undergo endoscopic resection * below 18 years of age.

Keywords: emr esd resection ster eftr submucosal dissection endoscopic resection
bioequivalence study of rivaroxaban

Conditions: Embolism, Atrial Fibrillation and Venous Thrombosis

Summary: the objectives of this study are to establish the bioequivalence between rivaroxaban tablet 15 mg and rivaroxaban granule formulation 15 mg, and to assess the safety and tolerability of rivaroxaban 15 mg in healthy adult male subjects.


Eligibility criteria:
inclusion criteria: * japanese healthy male subjects * 20 to 40 years of age * 17.6 to 26.4 kg / m² of body mass index (bmi) exclusion criteria: * subject with incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal * subject with a history of relevant diseases of vital organs, of the central nervous system or other organs, eg instable coronary heart disease, heart failure, liver failure, kidney failure, hypotension, or history of stroke or myocardial infarction * subject with known coagulation disorders (eg von willebrand's disease, hemophilia) * subject with known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) * subject with known sensitivity to common causes of bleeding (eg nasal)
understanding of participation trends within generalized anxiety disorder patients involved in clinical trials

Conditions: Generalized Anxiety Disorder

Summary: typically, certain demographic groups tend to participate more in medical research. however, there is insufficient research explaining the trial characteristics that influence the involvement of these specific demographics. this study aims to collect extensive data on the clinical trial experiences of individuals with generalized anxiety disorder. the goal is to identify the factors that hinder a patient's enrollment or completion of a trial. additionally, the research will examine the data from various demographic perspectives to identify recurring patterns that could offer valuable insights for future generalized anxiety disorder patients.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of generalized anxiety disorder * participant must be 18 years of age or older * participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. exclusion criteria: * pregnant or lactating woman * participant is actively receiving study therapy in another * inability to provide written informed consent

Keywords: generalized anxiety disorder